Hinge Health announced a new Migraine Care Program that extends its digital musculoskeletal platform to treat migraine sufferers. The program integrates the company’s Enso nerve‑stimulation device with exercise therapy and behavior‑change tools, offering rapid, drug‑free pain relief and personalized trigger management.
The Enso device, cleared by the FDA for migraine treatment, delivers electrical nerve stimulation to the occipital region, providing immediate relief for acute attacks while the digital platform supports ongoing prevention. The program also includes expert‑led coaching to help patients identify and avoid migraine triggers.
Market data underscore the program’s potential. Seventy‑five percent of migraine patients also experience musculoskeletal pain, and the condition drives more than $16,000 in annual medical and pharmaceutical spend per patient. U.S. businesses lose an estimated $78 billion each year to migraine‑related costs, a figure that includes direct medical expenses and lost productivity.
Hinge Health reports that 125 employers have already adopted the program, covering over two million employees. By adding migraine care to its portfolio, the company broadens its addressable market and strengthens its two‑sided marketplace moat, positioning it to capture a larger share of the $60 billion combined musculoskeletal and migraine care space.
"Migraine is one of the most disabling and widespread neurologic conditions, yet existing treatment options are insufficient," said Dr. Jeffrey Krauss, Chief Medical Officer. "The FDA recently cleared our proprietary Enso device for the treatment of migraine, enabling us to deliver a first‑of‑its‑kind care solution that combines groundbreaking technology with a full care team."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.